Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

MEN with the Angelina Jolie cancer genes should get routine prostate screening on the NHS from the age of 40, says the ...

Men with BRCA1 and BRCA2 gene mutations should be given annual prostate cancer screening checks, leading scientists have said ...

With the backing of Rishi Sunak, Prostate Cancer UK published a report to the national screening committee back in 2022 in ...

BRCA gene mutations are linked to a higher chance of developing prostate cancer at a younger age and in a more aggressive ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

MEN with aggressive prostate cancer could benefit from a new drug combination that slows cancer growth, scientists say.

An international study reports that the combination of two drugs could significantly retard the development of a dangerous ...

Men with BRCA1 and BRCA2 gene mutations should be offered annual PSA testing from the age of 40 to detect prostate cancer at ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...